Single agent etoposide in gestational trophoblastic tumours
- 1 June 1988
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 24 (6) , 1041-1046
- https://doi.org/10.1016/0277-5379(88)90156-3
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Primary oral etoposide therapy in gestational trophoblastic disease: An updateCancer, 1986
- Developments in chemotherapy for medium‐ and high‐risk patients with gestational trophoblastic tumours (1979–1984)BJOG: An International Journal of Obstetrics and Gynaecology, 1986
- Ovarian dysfunction in patients with gestational trophoblastic neoplasia treated with short intensive courses of etoposide (VP-16-213)Cancer, 1985
- Pharmacokinetics and toxicity of the epipodophyllotoxin derivative etoposide (VP 16-213) in patients with gestational choriocarcinoma and malignant teratomaCancer Chemotherapy and Pharmacology, 1985
- Enhancement of human chorionic gonadotrophin production by antimetabolitesBritish Journal of Cancer, 1982
- Anti-tumour activity of the epipodophyllin derivative VP16–213 (etoposide: NSC-141540) in gestational choriocarcinomaPublished by Elsevier ,1980
- Etoposide (VP-16-213)Cancer Treatment Reviews, 1979
- Risk and prognostic factors in trophoblastic neoplasiaCancer, 1976
- A rapid, sensitive and specific radioimmunoassay for human chorionic gonadotrophinJournal of Immunological Methods, 1976
- Treatment of metastatic trophoblastic disease: Good and poor prognosisAmerican Journal of Obstetrics and Gynecology, 1973